PAZOPANIB HCL

Pazopanib HCL is a tyrosine kinase inhibitor medication used in the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma.

REQUEST A QUOTE
Product successfully added to Quote Basket!
View Quote Basket

Demonstrates efficacy in the management of advanced renal cell carcinoma (RCC) and soft tissue sarcoma.

Pazopanib HCL hinders cancer progression while minimizing adverse effects on healthy tissues.

Available in oral form, allowing for convenient administration, which may improve patient compliance and quality of life during treatment.

Pazopanib HCL, an effective tyrosine kinase inhibitor, shows efficacy in treating advanced renal cell carcinoma (RCC) and soft tissue sarcoma by hindering cancer progression while minimizing adverse effects on healthy tissues. Its oral formulation offers convenient administration, potentially enhancing patient compliance and improving quality of life during treatment.

About MedicaPahrma

MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.

What is Pazopanib HCL

A tyrosine kinase inhibitor medication utilized in treating advanced renal cell carcinoma and soft tissue sarcoma.

Why Choose MedicaPharma

We are committed to supplying high-quality GMP products with logistics according to GDP regulations.

Table of Contents

Pazopanib HCL, a medication that inhibits tyrosine kinase, is employed to manage advanced renal cell carcinoma (RCC) and soft tissue sarcoma.

Mechanism of Action

Pazopanib operates by inhibiting multiple tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and fibroblast growth factor receptors (FGFRs). This inhibition impedes angiogenesis, the process of forming new blood vessels that tumors rely on for growth and metastasis. By targeting these key receptors involved in tumor vascularization and growth, pazopanib disrupts the tumor microenvironment, ultimately slowing cancer progression and reducing tumor size. Additionally, pazopanib’s inhibitory effects on angiogenesis can lead to decreased tumor vascularity and increased tumor necrosis, further contributing to its anticancer activity.

Benefits and Advantages

Pazopanib offers several advantages in the treatment of advanced renal cell carcinoma and soft tissue sarcoma. Firstly, its broad-spectrum inhibition of tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and fibroblast growth factor receptors (FGFRs), targets multiple pathways involved in tumor growth and angiogenesis. Secondly, pazopanib’s oral formulation allows for convenient administration, enhancing patient compliance and quality of life during treatment.

Additionally, pazopanib’s well-established safety profile and manageable side effects contribute to its suitability for long-term use in managing these malignancies. Finally, pazopanib’s ability to slow cancer progression and reduce tumor size provides patients with improved outcomes and potentially prolonged survival.

Side Effects and Risks

  • Hypertension: Pazopanib treatment may lead to elevated blood pressure, requiring monitoring and management to prevent cardiovascular complications.
  • Hepatotoxicity: Pazopanib has the potential to cause liver toxicity, characterized by elevated liver enzymes and hepatocellular injury, necessitating regular liver function tests during therapy.
  • Cardiac Toxicity: Pazopanib use has been associated with cardiac adverse effects such as QT interval prolongation, arrhythmias, and congestive heart failure, particularly in patients with preexisting cardiovascular conditions or risk factors.
  • Gastrointestinal Side Effects: Pazopanib can induce gastrointestinal adverse effects such as diarrhea, nausea, and vomiting, which may require supportive care or dose adjustments to alleviate symptoms and maintain treatment adherence.

Pazopanib HCL FAQ

Pazopanib HCL is a tyrosine kinase inhibitor medication utilized in the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma. By inhibiting multiple signaling pathways involved in tumor growth and angiogenesis, Pazopanib HCL slows cancer progression and improves outcomes for patients with these malignancies.
MedicaPharma, a supplier based in the European Union, offers GMP products with GDP-compliant logistics to hospitals, pharmacies, commercial (compounding) pharmacies, research institutes, and universities. For inquiries or to request a quote, please click here.
When choosing a pharmaceutical supplier, it’s vital to prioritize reliability, ensuring consistent and timely delivery of high-quality products. Additionally, expertise and compliance with regulatory standards are essential to guarantee the safety and efficacy of pharmaceutical supplies.
EU-based supplier MedicaPharma provides high-quality GMP products with logistics according to GDP regulations to leading sales, research, and education institutions. Click here to request a quote.